Mohammad Aljawadi PharmD, PhD Clinical Pharmacy Department King Saud University PHCL 431 Sep, 2015.

Slides:



Advertisements
Similar presentations
Workshop C – Evaluation Rod Taylor Complex Interventions Research Framework Masterclass 2010.
Advertisements

ECONOMIC EVALUATION WHY DO YOU NEED TO BOTHER? JUDITH BOSMANS.
9-0 Chapter 9: Outline Net Present Value The Payback Rule The Discounted Payback The Average Accounting Return The Internal Rate of Return The Profitability.
Net Present Value and Other Investment Criteria
1 Are you sure your improvements are cost-effective? Edward Broughton, PhD, MPH, PT University Research Co. April 11, 2014
Introduction to Pharmacoeconomics
1 Health and Disease in Populations 2002 Week 9 – 2/5/02 Randomised controlled trials 2 Dr Jenny Kurinczuk.
Economic Analysis and Management Todd Wagner, PhD.
Quality improvement for asthma care: The asthma care return-on-investment calculator Ginger Smith Carls, M.A., Thomson Healthcare (Medstat) State Healthcare.
Arda ÇELİK DEÜ Endüstri Mühendisliği ABSTRACT Cost analysis can play strategic roles in organizations and plans. As industrial engineers,
COST–EFFECTIVENESS ANALYSIS AND COST-UTILITY ANALYSIS
The Cost-effectiveness Analysis
Health care decision making Dr. Giampiero Favato presented at the University Program in Health Economics Ragusa, June 2008.
Making Cost Effectiveness Analyses more useful: Budget Impact Curves Christopher McCabe PhD Endowed Research Chair in Emergency Medicine Research University.
Investment, the Capital Market, and the Wealth of Nations
AGEC 608 Lecture 17, p. 1 AGEC 608: Lecture 17 Objective: Review the main aspects of cost- effectiveness analysis (CEA) and cost-utility analysis (CUA).
Sample Size Determination
Drug and Therapeutics Committee
Health Economics & Policy 3 rd Edition James W. Henderson Chapter 4 Economic Evaluation in Health Care.
Assessing cost-effectiveness – what is an ICER?- Incremental analysis
Chapter 5 Valuing Benefits and Costs in Secondary Markets
Economic Evaluations, Briefly… CHSC 433 Module 6/Chapter 13 UIC School of Public Health L. Michele Issel, PhD, R N.
1 Cost-effectiveness of improving medical services in low-resource settings Edward Broughton, PhD, MPH, PT University Research Co. May 21, 2014
Introduction to Pharmacoeconomics
1 Econoqualimetrics Edward Broughton, PhD., MPH Senior Economic Analyst, USAID Health Care Improvement Project, EnCompass,
Inference in practice BPS chapter 16 © 2006 W.H. Freeman and Company.
Cost-Benefit Analysis Delia Prieto University of Miami December 10, 2011.
Chapter 1 - Introduction & Research Methods What is development?
PHAR 310: Pharmacoeconomics
EVIDENCE BASED MEDICINE Health economics Ross Lawrenson.
Knowing what you get for what you pay An introduction to cost effectiveness FETP India.
What is a Clinical Trial (alpha version) John M. Harris Jr., MD President Medical Directions, Inc.
Pharmaceutical Economics Heng-Sim Lee RPh MS Director of Pharmacy, ChiaYi Branch, Taichung Veterans General Hospital Clinical Nutritional.
Economic evaluation of health programmes Department of Epidemiology, Biostatistics and Occupational Health Class no. 17: Economic Evaluation using Decision.
Pharmacists’ Expanded Scope of Practice in Canada as of Oct 2014 Source: Canadian Pharmacists Association.
Dispensing to in and out patients or Drug distribution system
317_L26, Mar J. Schaafsma 1 Review of the Last Lecture Are looking at program evaluation in healthcare Three methods: CBA, CEA, CUA discussed CBA,
Mohammad Aljawadi PharmD, PhD Clinical Pharmacy Department King Saud University PHCL 431 Sep, 2015.
Cost-Effectiveness and Cost-Benefit Analysis N287E Spring 2006 Joanne Spetz 31 May 2006.
Economic evaluation of health programmes Department of Epidemiology, Biostatistics and Occupational Health Class no. 19: Economic Evaluation using Patient-Level.
انواع ارزيابي های اقتصادي سيدرضا مجدزاده مرکز تحقيقات بهره برداری از دانش سلامت و دانشکده بهداشت دانشگاه علوم پزشکي و خدمات بهداشتي درماني تهران.
Course overview, the diagnostic process, and measures of interobserver agreement Thomas B. Newman, MD, MPH September 20, 2007.
Vanderbilt Sports Medicine Chapter 5: Therapy, Part 2 Thomas F. Byars Evidence-Based Medicine How to Practice and Teach EBM.
How to find a paper Looking for a known paper: –Field search: title, author, journal, institution, textwords, year (each has field tags) Find a paper to.
Economic evaluation of health programmes Department of Epidemiology, Biostatistics and Occupational Health Class no. 23: Nov 17, 2008.
PHARMACOECONOMICS Dr. Mohammad Aljawadi, PharmD PhD Department of Clinical Pharmacy King Saud University Aug, 2015 PHCL 431.
1 Study Design Issues and Considerations in HUS Trials Yan Wang, Ph.D. Statistical Reviewer Division of Biometrics IV OB/OTS/CDER/FDA April 12, 2007.
Software Project Management
Auctions serve the dual purpose of eliciting preferences and allocating resources between competing uses. A less fundamental but more practical reason.
Cost-Effectiveness and Outcomes Research Setting value to what we do.
Improving the Quality of Care of Sick Children in District Hospitals in Kenya: A Cost-Effectiveness Analysis Barasa W. E, Ayieko P, Cleary S, English M.
Conceptual Addition of Adherence to a Markov Model In the adherence-naïve model, medication adherence and associated effectiveness assumed to be trial.
Efficient:The correct answer about a treatment’s clinical benefit with as few subjects as possible as quickly as possible. Definitive:Yields results that.
© University of South Wales Royal College of Speech and Language Therapists Outcomes Conference and Hub Launch Belfast, May 1, 2014 Running a tight ship:
Presentation Developed for the Academy of Managed Care Pharmacy
Economic evaluation of health programmes Department of Epidemiology, Biostatistics and Occupational Health Class no. 7: Cost-effectiveness analysis – Part.
Chapter 14 Economic Analysis of Clinical and Managerial Interventions Copyright 2015 Health Administration Press.
Introduction Out-of-hospital cardiac arrest (OHCA) is the sudden cessation of the heart in an out of hospital setting. In the United States, the incidence.
Lecture 15 Assoc. Prof. Sencer Ecer HEALTH ECONOMICS
Teesside Liaison Psychiatry
Strategies to incorporate pharmacoeconomics into pharmacotherapy
NAPLEX preparation: Biostatistics
Health care decision making
Cost-effectiveness of oral phenytoin, intravenous phenytoin, and intravenous fosphenytoin in the emergency department  Maria I Rudis, PharmD, Daniel R.
Statistical significance using p-value
Pharmacoeconomic Dr . Dlivan F. Aziz.
Cholinesterase Inhibitors: Actions and Uses
Introduction to Clinical Pharmacology Chapter 4 The Nursing Process
Presentation Developed for the Academy of Managed Care Pharmacy
Presentation transcript:

Mohammad Aljawadi PharmD, PhD Clinical Pharmacy Department King Saud University PHCL 431 Sep, 2015

Upon completing this chapter, the pharmacy learner will be able to:  Define and describe cost-minimization analysis (CMA).  Address advantages and disadvantages of CMA.

 Definition: A comparison in which inputs are measured in monetary values and outcomes are assumed to be identical.  Measures and compares input costs  Assumes outcomes to be equivalent  Very crucial

 Comparing the cost of two medications:  Same chemical entity  Same dose  Same indication  E.g. brand vs. generic, Panadol® vs. Fevadol®  Measuring the cost of the same medication in different settings  IV antibiotic in hospital vs. IV antibiotic in nursing home

PGE2 2-hour monitoring period Send the expectant mother home for the night 2-hour monitoring period Send the expectant mother to the maternity unit overnight Apply

 Perspective: Payer  Direct medical cost were included  Authors found:  No difference between the two groups in the outcomes (% of cesarean section and amount of oxytocin needed)

Upon completing this chapter, the reader will be able to:  Define and describe cost-effectiveness analysis (CEA).  Address the advantages and disadvantages of CEA.  Discuss the different methods of presenting cost- effectiveness results.  Illustrate the use of a cost-effectiveness grid and a cost- effectiveness plane.  Compare intermediate- with final-outcome measurements.  Compare the terms “efficacy” and “effectiveness.”

 A comparison in which inputs are measured in monetary units and outcomes are measured in natural units of effectiveness.  CEA measures outcomes in natural units (e.g., mmHg, cholesterol levels, symptom-free days [SFDs], years of life saved)  Easy to comprehend by clinicians  Easier than CBA or CUA

 What cannot CEA measures:  Cannot compare different types of outcomes Implementation of an anticoagulation clinic with implementation of a diabetes clinic Antihypertensive drug vs. asthma drug Antihypertensive drug vs. antihypertensive drug but different outcomes Life-years saved vs. number of mmHg reduction

 Patients with symptoms of stomach ulcer  Diagnosis can be made based on: Symptomology Endoscopy  Outcomes: Symptom-free days / year  Number of days without any gastrointestinal (GI) sumptoms % of patients healed  based on endoscopic results

 Method 1:  Inputs are measured in monetary values and outcomes are listed in a variety of ways.

16  Positive ICER  More costly; more effective  Less expensive; less effective

17  Negative ICER  More costly; less effective  Less expensive; more effective

 Dominant: The treatment of interest is both more effective and less expensive than a comparator treatment.  Dominated: The treatment of interest is both less effective and more expensive than a comparator product.  The ICER is used to determine the magnitude of the added cost for each unit in health improvement.

N EW S SW NE

N EW S SW NE A B C

 Not easy to determine a confidence interval around the ICER  It does not answer whether the intervention is more cost- effective, that is, is the added benefit worth the added cost?  It depends on how much you are willing to pay

 Willingness to Pay (λ):  The estimate of how much people are willing to pay to reduce the chance of an adverse health outcome or increase the change of a positive outcome

30  Vary value of λ  Plot cost-effective replicates against λ  At λ=$100, 90% of replicates are CE Probability CE λ

 Intermediate vs. Primary outcomes:  Primary outcomes are preferred over intermediate unless there is strong association between them.  Efficacy vs. Effectiveness:  Efficacy: Outcomes measured under controlled conditions (usually randomized, controlled trials).  Effectiveness: Outcomes measured in the “real world” or routine clinical practice.

should NOT discount: Should discount: 1)Health can’t be invested i.e. you can’t save one life year and now and use it in the future or yield additional life year in the future. 1) Although health can’t be invested people are willing to make changes in their life to enjoy healthier life in the future. Otherwise we would not have seen people abstaining from pleasurable unhealthy behaviors. 2) If you discount this means that you give more weight for current generation than future generation. 2)The fact that we are putting more weight in current generation than future doesn’t take in its account that future generations will have more health technology advantages.In addition, with the positive economic growth since World War II people are getting healthier and richer over time. Therefore by not discounting we are shifting resources from sick individuals to healthier individuals. 3)Preventive programs that have their health benefits in the future will not implemented if discounting was carried out since the benefit will appear smaller compared to programs that have immediate health benefits. 3)If two programs have the same discounted cost and the same Undiscounted health benefits (e.g. 100LY) however one of them (program A) obtains the HB within one year and the other (program B) after 50 years, they will have the same ICER. In addition, if program B gives one extra day as benefit over program A then program B will be more cost effective which doesn’t make sense. If we don’t discount this means that we will have constant return of health benefits over time and therefore we should implement the program regardless of the initial cost since at one point of time the program will be cost effective.